Not available
Quote | aTyr Pharma Inc. (NASDAQ:LIFE)
Last: | $1.60 |
---|---|
Change Percent: | -1.85% |
Open: | $1.65 |
Close: | $1.60 |
High: | $1.65 |
Low: | $1.58 |
Volume: | 158,056 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
News | aTyr Pharma Inc. (NASDAQ:LIFE)
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcom...
2024-03-26 14:19:17 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips When it comes to deciding whether you should acquire penny stocks or not, the answer is no. Okay, so we’re done here, right? Of course, human nature being what it is, people are ...
Message Board Posts | aTyr Pharma Inc. (NASDAQ:LIFE)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $LIFE News Article - aTyr Pharma Announces Achievement of Development Milestone by Part | whytestocks | investorshangout | 02/06/2023 3:25:46 PM |
whytestocks: $LIFE News Article - aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod | whytestocks | investorshangout | 04/13/2022 2:55:59 PM |
whytestocks: $LIFE News Article - aTyr Pharma Announces Positive End-of-Phase 2 Meeting with FDA on | whytestocks | investorshangout | 03/10/2022 6:40:52 PM |
whytestocks: $LIFE News Article - Love Hemp Group PLC Announces Directorate Change and Issue of Shar | whytestocks | investorshangout | 02/22/2022 9:45:53 PM |
Top Meme Stock Mentions Money to Move 12/30/2021 $LIFE: | LordTurkeyBaster | investorshub | 12/30/2021 2:00:02 PM |
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery a...
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcom...